NCT07073820

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

A PHASE 2, OPEN-LABEL EXTENSION STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF PF-07868489 ADMINISTERED TO ADULT PARTICIPANTS WITH PULMONARY ARTERIAL HYPERTENSION

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 36 (estimated)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to learn about the long-term safety, tolerability and effects of the study medicine (PF-07868489) for the possible treatment of PAH. PAH is a condition in which there is high blood pressure in the arteries that carry blood from the heart to the lungs. This high pressure makes it harder for the heart to pump blood through those lungs, potentially damaging the right side of the heart. This is an open-label study. Which means that both the healthcare providers and the study participants are aware of the medicine being given. This study is also an extension study with study medicine (PF-07868489). An extension study allows patients from an earlier clinical study (also called as qualifying study) to continue participating to assess long-term benefits and safety of the medicine.

Conditions

• Pulmonary Hypertension

Interventions

Type	Name	Description
DRUG	PF-07868489	Participants will receive subcutaneous doses of PF-07868489 every 4 weeks

Timeline

• Start date: 2025-11-10
• Primary completion: 2028-07-18
• Completion: 2028-07-18
• First posted: 2025-07-18
• Last updated: 2026-04-14

Locations

43 sites across 14 countries: United States, Australia, Belgium, Canada, China, Czechia, France, Germany, Greece, Italy, Japan, South Korea, Spain, United Kingdom

Regulatory

• FDA-regulated drug study